Equity vs. Cash: The Startup Compensation Question

The offer arrived on a Thursday afternoon, and it asked her to accept a discount. A product manager in Seattle with five years of experience had been quoted $160,000 to $170,000 for comparable roles at larger companies. The startup, a Series C firm of about 140 employees, offered $135,000 in base salary plus 12,000 incentive stock options at a strike price of $1.40. The recruiter called the grant "the real upside." The offer letter did not say what the shares might be worth at an exit, when she could sell them, or what would happen to them if she left after a year. She had five days to decide.

That decision now sits inside a significant share of American job offers, and it turns on a question most candidates never learn to answer: what is the equity actually worth? At public companies, restricted stock units are routine and fairly easy to price. At private startups, the instruments are stock options, the terms are dense, and the tax rules can produce surprises years after signing. What follows is how the instruments differ, what the data say about startup outcomes, and a framework for deciding how much salary to trade for a claim on a company's future.

The timing gives the question fresh weight. Startup hiring has cooled since the boom of 2021 and 2022, and the independent appraisals that set option strike prices fell with it, making new grants cheaper to exercise. Equity remains the standard sweetener in offers from venture-backed companies, and candidates are still asked to weigh it against cash they could deposit today. The numbers that would make that comparison honest are available before signing. Few people ask for them.

The three instruments

Restricted stock units are the simplest form. The company promises a set number of shares that vest over time — four years with a one-year cliff is the standard schedule — and when they vest, the shares are yours, taxed as ordinary income at their fair market value. RSUs dominate at public companies and have spread to late-stage private firms that prefer to skip option complexity. Their value is transparent: multiply the share count by the current price, subtract roughly a quarter to a third for taxes, and that is what you have.

Stock options work differently, and the difference is the source of most confusion. An option is the right to buy one share at a fixed price, called the strike price, no matter what the share is worth later. If the strike is $1.40 and the company is eventually sold for the equivalent of $10 a share, the option is worth $8.60. If the company is sold for less than $1.40 a share, the option is worthless, and it expires that way. Options come in two tax flavors. Incentive stock options, or ISOs, are what startups prefer to grant: exercised and held, they can produce long-term capital gains treatment for the employee, and the company pays no payroll tax on them. Nonqualified options, or NSOs, are taxed as ordinary income on the gap between strike and market value at exercise, and the employer takes a deduction. The distinction sounds like bookkeeping until tax season.

Early-stage grants add a third shape. At a seed-stage company you may be offered the chance to buy common shares directly, or a small grant priced off a valuation that exists mostly on paper. The stakes are the same family but steeper: there is no market price to check, the company may raise money at a lower valuation than the one you bought at, and your shares sit behind everyone else's in a sale.

There is also the matter of units. An option grant is quoted in shares — 12,000 options, 50,000 options — which sounds like a lot and tells you nothing. What matters is the percentage of the company, and that requires the fully diluted share count: all shares outstanding plus everything reserved for the option pool. Twelve thousand options against 40 million fully diluted shares is 0.03 percent of the company. Against 4 million shares, the same grant is 0.3 percent — ten times the stake, same paperwork. The share count is the first thing to ask for, and the second thing to check.

What most exits actually return

The uncomfortable statistic is the foundation of the whole subject: most venture-backed startups fail or return little to their employees. Research at Harvard Business School on thousands of venture-backed companies found that roughly three-quarters never returned investor capital. Analyses by the Kauffman Foundation reached a related conclusion — venture funds as a group have long earned about what public markets return, once fees are counted. The glamour outcomes that make startup equity famous are the tail of a distribution, and employee stock sits at the back of that tail: common stock is paid only after preferred investors take their share.

The numbers that come out of real exits confirm it. A company that raises $40 million and sells for $45 million has not failed exactly, but its common shareholders — founders, early employees, option holders — typically receive little or nothing, because the preferred shareholders' liquidation preference absorbs nearly the entire sale price. A sale for three times the money raised is, for employees, often a rounding error. A sale for twenty times the money raised is where option holders finally get paid, and those sales are uncommon.

The pattern shows up in individual careers, too. A former engineer in Boulder described a company he joined at Series A; it sold eight years later for $38 million after raising $31 million. The acquisition was announced internally as a win, the press release used the word "growth," and his options — he had accrued them across four years — paid out about $4,000. He said he kept the email from the equity administrator as a reminder.

Time is the other silent tax. The median stretch from founding to a liquidity event runs roughly seven to nine years, while the typical option vests over four. Most employees who hold options never see an exit at all: they leave, face a short window to exercise, and let the grant lapse, or they stay and watch the company raise round after round at flat valuations. A grant that survives to liquidity is the exception, not the rule — which is another way of saying the statistics above overstate what the typical employee actually collects.

Dilution, preferences, and the 409A

Three mechanisms quietly shrink the value of a grant between the day you sign and the day you cash out. The first is dilution. Every funding round prints new shares, and your percentage of the company falls accordingly. A 0.25 percent grant at a Series A is commonly worth 0.15 percent of the company by the time of an exit, once later rounds and option-pool top-ups are counted. Equity-administration data from Carta show that companies typically reserve 10 to 20 percent of shares for employees, and each new round often enlarges that pool at everyone's expense.

The second is the liquidation preference, the clause that decides who gets paid first in a sale. The modern standard is a 1x non-participating preference: preferred investors get their money back before common stock sees a dollar, then convert and share what remains. Some deals carry participating preferences, which let investors take their money back and then share in the remainder too — a structure that can leave common stock with almost nothing even in a respectable sale. The preference terms live in the financing documents, not your offer letter, and most candidates never see them.

The third is the 409A, the independent appraisal that sets your strike price. It matters because the strike price is the single most important number in your grant: the lower it is, the more of the exit value you keep. A fresh, defensible 409A valuation is required for a company to grant options without tax penalties, and the rules for it come from the IRS. When a strike price looks suspiciously low — pennies against a headline valuation of hundreds of millions — it usually reflects a recent markdown, not a gift. Check the date on the appraisal.

The tax traps: 83(b) elections and the AMT

Taxes can undo the math of a good grant, and two rules account for most of the damage. The first is the Section 83(b) election, available when you buy shares outright, as opposed to holding options. Filing an 83(b) within 30 days of the purchase lets you pay tax now on the current fair market value and lock in capital gains treatment on everything later. Miss the window and you will owe ordinary income tax on the full spread between the purchase price and the value at the moment the shares vest — a bill that can arrive years after the fact, on a company whose value has moved in either direction. The form is simple; the deadline is not forgiving. IRS guidance on restricted stock and Section 83(b) runs to many pages for a reason.

The second trap is the alternative minimum tax, and it attaches to ISOs. When you exercise an incentive stock option, the gap between the strike price and the current fair market value counts as income for AMT purposes even though you have sold nothing. During the boom years of 2021 and 2022, employees at private companies exercised options at appraised values that later collapsed; some owed AMT on paper gains that no longer existed, with no ability to sell shares to cover the bill. The tax code's remedy, a credit that carries forward, helps eventually, but "eventually" is cold comfort when the bill is due. The IRS AMT materials and a tax professional's calculator are worth consulting before you exercise, not after.

There is a third rule worth knowing if you do exercise and hold: to keep the favorable long-term capital gains rate on ISOs, you generally must hold the shares for at least one year after exercise and two years after the grant. Sell earlier and the gain is taxed as ordinary income — a detail that quietly converts many "long-term" gains into short-term ones. For RSU holders the picture is simpler but still needs planning: shares are taxed as ordinary income when they vest, and many companies sell a portion automatically to cover withholding. What lands in your brokerage account is the after-tax remainder.

How much salary to trade for equity

The framework for the decision is straightforward, if uncomfortable: assign probabilities to outcomes and multiply. Start with your fully diluted percentage — the share count of your grant divided by all shares outstanding, including the option pool and shares reserved for future rounds. Then estimate what the company is worth in four or five scenarios: no exit, a small sale, a mid-size sale, and a genuine home run. Weight each by an honest probability and compare the expected value to the salary you are giving up over the vesting period.

A worked example

A worked example shows how the comparison usually lands. Take the product manager from the top of this article: a $30,000 annual gap, about $120,000 foregone over four years, and a grant of 12,000 options at $1.40 against 40 million fully diluted shares. If the company exits at $1 billion — a top-tier outcome — each share is worth $25, her options clear roughly $280,000 before taxes. If the company exits at $60 million, a far more common destination, each share is worth $1.50 and the grant pays about $1,200 after the strike price. If the company never exits, the grant is nothing. Weight those outcomes by what the data say, and the expected value of the equity is a small fraction of the $120,000 gap.

Illustrative pre-tax values for a 0.03 percent grant at a Series C company

Outcome	Rough likelihood	Value of grant
No exit or write-off	About 1 in 2	$0
Sale below $60 million	About 3 in 10	$1,200 or less
Sale of $60M–$300M	About 1 in 6	$1,200–$73,000
Sale above $300M	Under 1 in 20	$73,000 or more

The table is illustrative, not a prediction — every company is different — but the shape is the point. The median outcome for employee equity is close to zero, and the distribution is so skewed that the average tells you nothing about your own grant.

That is why compensation consultants who review offers for a living tend to work with a blunt heuristic: discount the equity by half to 90 percent when comparing offers, and if the discounted figure does not beat the cash difference, take the cash.

"Candidates treat equity like a lottery ticket, and they're right about the odds. The mistake is paying face value for the ticket."

A compensation consultant in San Francisco who has reviewed hundreds of startup offers and asked not to be identified offered that assessment unprompted, after walking through a grant that a candidate had been describing as "found money."

There are reasons to take less cash beyond the numbers — belief in the company, a seat at a growing table, the chance to work on something that matters. Price those as what they are: preferences, not assets. The cash difference is the cost of the ticket, and the ticket's expected value is what the scenarios above estimate.

Before you sign

The questions worth asking are specific, and the answers are telling. Ask for the fully diluted share count and your percentage of it, not just the option count. Ask for the date and value of the most recent 409A. Ask what happens to your options if you leave: the industry default is a 90-day exercise window after departure, which forces a choice between paying the strike price on shares you cannot sell or walking away from the grant entirely; some companies now extend that window to seven or ten years. Ask about vesting acceleration in an acquisition — single trigger, which vests everything on a sale, versus double trigger, which requires a sale plus a termination. Ask whether the exercise price can be paid with a net exercise or a loan. A recruiter who answers these questions plainly is a signal; a recruiter who hedges every one is a signal of a different kind.

The comparison also has a cash side that people rarely price. The salary you give up is not merely absent; it is money you could have invested. Over four years, $120,000 in foregone pay, put into an ordinary index fund at historical returns, would grow to roughly $160,000 — with no strike price, no liquidation preference, and no 90-day window attached. Tools like the salary calculators and future-salary projections on this site can run that arithmetic in a few minutes. Equity has to beat that baseline, not just beat zero.

The direction of the industry is, if anything, friendlier to employees than it was a decade ago. Extended exercise windows have spread from a handful of high-profile companies to a wider field, and late-stage firms increasingly grant RSUs with the same mechanics public companies use. The tax rules will keep changing at the margins, but the structure of the trade — cash today for a claim on tomorrow — will not.

The practical takeaway is simple enough to carry into any negotiation. Price the grant in four scenarios, discount it, and compare it to the salary you are giving up. If the equity clears the bar, negotiate the strike details and the exercise window as hard as you negotiate the number. If it does not, take the cash, and treat the options as a bonus that may or may not arrive. The offer letter will not do this work for you; the data say most grants are worth far less than they look, and the ones that are worth more are the ones you priced before signing.